Sinopharm (Beijing): BBIBP-CorV
Vaega 1
1 Faʻamasinoga
ChiCTR2000032459
Saina
Vaega 2
2 Tofotofoga
NCT04962906
Argentina
ChiCTR2000032459
Saina
Vaega 3
6 Faʻataʻitaʻiga
NCT04984408
ChiCTR2000034780
United Arab Emirates
NCT04612972
Peru
NCT04510207
Bahrain, Aikupito, Jordan, United Arab Emirates
NCT04560881, BIBP2020003AR
Argentina
NCT04917523
United Arab Emirates
Faamaonia
Lisi o Faʻalavelave Faʻafuaseʻi a le WHO 59 Atunuʻu
Angola 、 Atenitina 、 Bahrain 、 Bangladesh 、 Belarus 、 Belize 、 Bolivia (Plurinational State of) 、 Pasila 、 Brunei Darussalam 、 Kemupotia 、 Cameroon 、 Chad 、 Saina 、 Comoros 、 Aikupito 、 Equatorial Guinea 、 Gabon 、 Gambia 、 Georgia 、 Guyana 、 Hungary 、 ndonesia 、 Iran (Islamic Republic of) 、 Iraq 、 Jordan 、 Kyrgyzstan 、 Lao People's Democratic Republic
Lepanona 、 Malaysia 、 Maldives 、 Mauritania 、 auritius 、 Mongolia 、 Montenegro 、 Morocco 、 Mozambique 、 Namibia 、 Nepal 、 Niger 、 North Maketonia 、 Pakistan 、 Paraguay 、 Peru 、 Philippines 、 Republic of the Congo 、 enegal 、 Serbia 、 Seychelles 、 Sierra Leone 、 Solomon Motu 、 Somalia 、 Sri Lanka 、 Thailand 、 Trinidad ma Tobago 、 Tunisia 、 United Arab Emirates 、 Venesuela (Bolivarian Republic of) 、 Viet Nam 、 Zimbabwe
Sinopharm BBIBP-CorV COVID-19 o se tui e le faʻagaoioia na faia mai ni siama ua tupu i le aganuu ua leai ni uiga faʻamaʻi. O lenei sui tauva tui na faia e Sinopharm Holdings ma le Beijing Institute of Biological Products.
O le tui Sinopharm BBIBP-CorV e galue i le faʻatagaina o le puipuiga e fausia ni vailaʻau teteʻe i le SARS-CoV-2 beta coronavirus. Ua leva tausaga o faʻaogaina tui puipuia o siama e le toe faʻagaoioia, pei o tui ole rabies ma tui ole hepatitis A. Lenei atinaʻe tekonolosi ua manuia faʻaoga i le tele lauiloa tui, pei o le tui puipuia o le rabies.
Sinopharm's SARS-CoV-2 ituaiga (WIV04 faʻamaʻi ma le faletusi numera MN996528) na vavaeʻese mai se tagata gasegase i Jinyintan Falemai i Wuhan, Saina. O le siama na faʻasalalauina i le aganuʻu i totonu o le Vero cell laina agavaʻa, ma o le supernatant o siama sela na faʻaaogaina i le β-propiolactone (1: 4000 vol / vol, 2 i le 8 ° C) mo le 48 itula. Ina ua maeʻa faʻamalamalamaina o sela otaota ma ultrafiltration, o le lona lua β-propiolactone inactivation na faia i lalo o le tutusa aiaiga pei o le muamua inactivation. Ae faimai foi WHO, o le tui na faapipiiina i luga o le 0.5 mg o le alum ma utaina i totonu ua uma ona tuiina tui i le 0.5 mL o sterile phosphate-buffered saline e aunoa ma se preservatives.
Ia Tesema 31, 2020, na faasilasila mai ai e le Setete o Vailaau Faasaina le faamaoniga o le tui faataitai na faia e Sinopharm.
Ia Me 7, 2021, na faasilasila mai ai e le Faalapotopotoga o le Soifua Maloloina a le Lalolagi le faamaoniga o le tui. O le lisi o faʻalavelave faʻafuaseʻi a le WHO na mafai ai e atunuʻu ona faʻavavevave a latou lava faʻatulafonoina faʻamaoniga e faʻaulu mai ma faʻatautaia le vailaʻau o le COVID-19. Ua maeʻa foi le iloiloga a le WHO Advisory Expert Group on Immunization Strategies e uiga i tui puipui. Faʻavae i luga o faʻamaoniga uma o loʻo avanoa, ua fautuaina ai e le WHO ni tui se lua o tui, tolu i le fa vaiaso le va, mo tagata matutua 18 tausaga pe sili atu. O le aoga o le vailaʻau faʻasaga i faʻailoga ma faʻamaʻi i le falemaʻi e tusa ma le 79% mo tausaga uma ua tuʻufaʻatasia.
Na lolomiina e le American Medical Association "Se Faʻataʻitaʻiga Togafitiga Faʻafuaseʻi: Aʻafiaga o Tui e 2 ua le faʻaaogaina SARS-CoV-2 i luga o le faʻamaʻi o le COVID-19 Faʻamaʻi i Tagata Matutua" ia Me 26, 2021, faʻaiʻuina ai e faapea "i lenei faʻamaoniga suʻesuʻe le tumau o se faʻataʻitaʻiina faʻafomaʻi falemaʻi, tagata matutua O tui e 2 ua le faʻaaogaina SARS-CoV-2 o loʻo faʻatautaia i lenei suʻesuʻega le tumau o faʻataʻitaʻiga faʻafomaʻi faʻafuaseʻi na faʻaititia ai le aʻafiaga o le COVID-19 faʻailoga, ma e seasea tutupu ni faʻalavelave matuia. " I lenei vaega 3 faʻasolosolo faʻataʻitaʻiina tagata matutua, o le aoga o le 2 ua le toe faʻagaoioia siama siama i faʻailoga COVID-19 mataupu e 72.8% ma 78.1%. E 2 ni tui na seasea tupu ai ni faʻalavelave matuia ma le tutusa tutusa i le vaega e naʻo le pule a le aliʻi, ma o le toʻatele e leʻi fesoʻotaʻi i tui. O se suʻesuʻega suʻesuʻe na maua ai o tui e 2 na faaosofia ai le fuaina o vailaʻau e mafai ona faʻamamaina, e tali tutusa ma iʻuga o le laasaga 1/2 faʻataʻitaʻiga.
O le WHO SAGE Working Group na lolomiina le toe iloiloga o le tui o le Sinopharm / BBIBP COVID-19 ia Me 10, 2021. O le tui puipuia a le GAVI's COVID-19 ua aofia ai se siaki fagu vailaʻau e taʻu atu ai i le aufaigaluega soifua maloloina pe na teu lelei le vailaʻau ma e leʻi faʻaalia. soona vevela. O lona iʻuga, faʻaleagaina, na lipotia mai e le GAVI ia Me 14, 2021. o ni igoa atamai na fausia e le Zebra Technologies ma faia e le Temptime Corporation, e aofia ai se liʻo ma se sikuea lanu malamalama i le ogatotonu, na faia i se vailaʻau leai se lanu e le mafai ai ona toe fesuiaʻi lanu i le aluga o taimi. . E atili ai ona pogisa e tuʻuina mai ai se faʻailoga vaʻaia o le vevela o le vevela. O le taimi lava na aliali mai ai le fagu i le vevela i talaatu o lona tulaga teu lelei, o le sikuea ua pogisa nai lo le liʻo, ua faʻailoa mai ai e le tatau ona toe faʻaaogaina le vailaʻau.
Faletupe a le Atunuʻu BBIBP-CorV COVID-19 numera o le faʻamaumauga o vailaʻau o tui puipui: DB15807.
